search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    Autolus Therapeutics plc

    (NASDAQ:AUTL)

    $2.5

    $0.14

    5.93%

    Autolus Therapeutics plc Chart

    AUTL Stock Price Today

    Autolus Therapeutics plc (AUTL) stock rallied over 5.93% intraday to trade at $2.50 a share on NASDAQ. The stock opened with a gain of 7.76% at $2.37 and touched an intraday high of $2.7, rising 5.93% against the last close of $2.36. The stock went to a low of $2.37 during the session.

    Stock Snapshot

    $2.36

    Prev. Close

    210.93 Million

    Market Cap

    $2.37

    Day Low

    $2.37

    Open

    82.02 Million

    Number of Shares

    $2.7

    Day High

    -

    P/E ratio

    -1.85

    EPS (TTM)

    3.41

    Cash Flow per Share

    6.41

    Free Float in %

    3.36

    Book Value

    225,626

    Volume

    Autolus Therapeutics plc Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$2.37$2.7$2.37$2.5225,600
    2022-06-22$2.32$2.466$2.32$2.3692,100
    2022-06-21$2.3$2.434$2.3$2.39109,100
    2022-06-17$2.08$2.26$2.08$2.22185,100
    2022-06-16$1.99$2.09$1.96$2.06328,600
    2022-06-15$2.31$2.45$2$2.04239,300
    2022-06-14$2.29$2.31$2.19$2.25147,800
    2022-06-13$2.57$2.57$2.24$2.28206,000
    2022-06-10$2.78$2.79$2.45$2.56366,800
    2022-06-09$2.82$2.86$2.76$2.7878,900

    Contact Details

    The MediaWorks
    191 Wood Lane White City
    London W12 7FP
    United Kingdom

    Webiste:AUTL

    44 20 3829 6230

    Company Information

    Employees-

    Beta1.61

    Sales or Revenue2.33 Million

    5Y Sales Change6.60%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

    Frequently Asked Questions

    icon

    What is the current Autolus Therapeutics plc (AUTL) stock price?

    Autolus Therapeutics plc (NASDAQ: AUTL) stock price is $2.5 as of the last check on Thursday, June 23. During the trading session, AUTL stock reached the peak price of $2.7 while $2.37 was the lowest point it dropped to.

    icon

    AUTL's industry and sector of operation?

    The NASDAQ listed AUTL is part of Biotechnology industry that operates in the broader Health Care sector. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

    icon

    Who are the executives of AUTL?

    Mr. Andrew J. Oakley
    Sr. VP & CFO
    Dr. Lucinda Crabtree Ph.D.
    VP of IR, Corp. Communications, Bus. Strategy & Planning
    Mr. Vishal Mehta
    VP & Head of Clinical Operations
    Mr. Brent Rice
    VP & Chief Commercial Officer

    icon

    What is the AUTL stock price today?

    AUTL stock traded closed the last session at $2.5, which is $0.14 or 5.93% lower than its previous close of $2.36. AUTL's current trading price is 27.55% lower than its 52-week high of $7.90 where as its distance from 52-week low of 1.96% is -68.35%.

    icon

    How many employees does AUTL have?

    Number of AUTL employees currently stands at -. AUTL operates from The MediaWorks, 191 Wood Lane White City, London W12 7FP, United Kingdom.

    icon

    Link for AUTL official website?

    Official Webiste of $AUTL is: https://www.autolus.com

    icon

    How do I contact AUTL?

    AUTL could be contacted at AUTL operates from The MediaWorks, 191 Wood Lane White City, London W12 7FP, United Kingdom, or at phone #44 20 3829 6230 and can also be accessed through its website.

    icon

    How many shares of AUTL are traded daily?

    AUTL stock volume for the day was 225,626 shares while in the previous session number of AUTL shares traded was 225,600 . The average number of AUTL shares traded daily for last 3 months was 218.47 Thousands.

    icon

    How much did AUTL change today?

    The percentage change in AUTL stock occurred in the recent session was 5.93% while the dollar amount for the price change in AUTL stock was $0.14.

    icon

    What price range AUTL stock been trading in?

    In the recent session, the day high for AUTL stock was $2.7 while the low for AUTL stock touched on the day was $2.37.

    icon

    What is the market cap of AUTL currently?

    The market value of AUTL currently stands at 210.93 Million with its latest stock price at $2.5 and 82.02 Million of its shares outstanding.